| Literature DB >> 35197075 |
Desta Assefa1, Getahun Paulos2, Dereje Kebebe2, Sintayehu Alemu2, Wondu Reta2, Temesgen Mulugeta2, Fanta Gashe2.
Abstract
BACKGROUND: Pharmaceutical compounding ensures access of individuals with specific requirements to individualized therapy. However, there is an inconsistency of compounded medication quality. Therefore, advancing the rational use of compounded medication is essential for patient safety and medication effectiveness.Entities:
Keywords: Antimicrobial resistance; Compounding; Healthcare practitioners; Rational use
Mesh:
Substances:
Year: 2022 PMID: 35197075 PMCID: PMC8864796 DOI: 10.1186/s12913-022-07649-4
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Demographic characteristics of healthcare practitioners in the healthcare facilities
| No. = 300, 100% | ||||||
|---|---|---|---|---|---|---|
| Sex | Male | 176 (58.7) | Respondent profession | Physician | 28 (9.3) | |
| Female | 124 (41.3) | Medical laboratory | 24 (8) | |||
| Age (years) | 20–30 | 175 (58.3) | Nursing | 54 (18) | ||
| 30–35 | 66 (22) | Pharmacy | 188 (62.7) | |||
| 35–40 | 23 (7.7) | Midwives | 6 (2) | |||
| > 40 | 36 (12) | |||||
| Educational level | Diploma | 142 (47.3) | Work experience (years) | < 5 | 151 (50.3) | |
| First degree | 145 (48.3) | 5–10 | 92 (30.7) | |||
| Specialty (Master degree) | 13 (4.4) | > 10 | 57 (19) | |||
| Took training on compounding medications | 73 (24.3%) | |||||
Reasons for performing extemporaneous compounding of medications and route of administration
| Reasons for performing extemporaneous compounding of medicine | No. = 300, 100% |
|---|---|
| Unavailability of prepackaged products in the market | 233 (77.7) |
| Unavailability of needed dosage regimen (dose, form) (individualized therapy) | 217 (72.3) |
| The product was discontinued by the manufacturer | 81 (27) |
| To combine two or more active ingredients into one product | 128 (42.7) |
| To improve adherence to medications (flavor, taste) | 68 (22.7) |
| Allergy to the excipient(s) in the commercially available product | 87 (29) |
| Compounded medications are less expensive | 90 (30) |
| Ministry of Health encourages compounding | 65 (21.7) |
| Improving the stability of the desired product | 61 (20.3) |
| Oral | 214 (71.3) |
| Ophthalmic | 148 (49.3) |
| Topical (Skin) | 121 (40.3) |
| Parenteral | 89 (29.7) |
| Otic | 82 (27.3) |
| Rectal | 44 (14.7) |
| Nasal | 32 (10.7) |
| Inhalation | 24 (8) |
| Rectal | 44 (14.7) |
| Others | 5 (1.7) |
Fig. 1Actual practicing of the rational use of extemporaneously compounded medications
Challenges to practice rational use of extemporaneously compounded antimicrobial medicine
| Challenges | No. = 300, 100% | |
|---|---|---|
| Lack of trust in the quality of the compounded formulations | 147 (49) | |
| Belief that compounded formulations have poor patient compliance | 122 (40.7) | |
| Compounded prescriptions are inconvenient economically | 49 (16.3) | |
| Belief that the ministry of health does not allow compounded formulations | 33 (11) | |
| not adequate | skilled personnel | 49 (16.3) |
| manufacturing environment | 80 (26.7) | |
| no ingredients | 50 (16.7) | |
| Fear of inappropriate use (overuse or underuse) | 67 (22.3) | |
| Fear of AMR development | 73 (24.3) | |
| other (specify) | 3 (1) | |
Perception and knowledge of healthcare practitioners on the contributions of antimicrobial compounding to antimicrobial resistance
| Statements for perception evaluation | N | ||||||
|---|---|---|---|---|---|---|---|
| strongly agree | Agree | Neutral | Disagree | Strongly disagree | Don’t know | ||
| More cautious use of antimicrobials in extemporaneous formulations would decrease AMR | 93 (31) | 95 (31.7) | 45 (15) | 6 (2) | 21 (7) | 40 (13.3) | |
| For extemporaneous compounding, using broad-spectrum antimicrobials can be used in place of narrow-spectrum antimicrobials to reduce resistance | 37 (12.3) | 82 (27.3) | 101 (33.7) | 46 (15.3) | 12 (4) | 22 (7.3) | |
| Inappropriate or substandard extemporaneous compounding of antimicrobials contributes to AMR development | 112 (37.3) | 46 (15.3) | 49 (16.3) | 11 (3.7) | 20 (6.7) | 62 (20.7) | |
| Factors contribution for AMR development | Under dose administration | 177 (59) | |||||
| Contamination | 86 (28.7) | ||||||
| Inappropriate preparation process due to lack of standard operating procedures | 225 (75) | ||||||
| Ineffectiveness nature of compounded preparation | 47 (15.7) | ||||||
| Incompatibility between drug and excipient(s) | 46 (15.3) | ||||||
| Using after beyond use date | 44 (14.7) | ||||||
| Other (specify) | 2 (0.7) | ||||||